Skip to main content
Practical Issues in Pharmacy Management, Biosimilars, Cost of Care, Adverse Events
Biosimilars in Oncology Practice: A Multi-Site Health System Examination of the Use and Perception of Oncology Biosimilars
Ashley Chen, PharmD, BCOP; Taylor Dennison PharmD; Shannon Palmer, PharmD, BCOP; Cameron Czech, PharmD; Erin Mays Eberwein, PharmD, BCOP; Ashley L. Pappas, PharmD, MHA; Mary-Haston Vest, PharmD, MS, BCPS; Walter Russell Laundon, PharmD, MS, BCPS; Maurice Alexander, PharmD, BCOP
Read More
Original Research, Cost of Care, Adverse Events, Biosimilars, VEGF Inhibitors
Real-World Tolerability and Financial Impact of Biosimilar Bevacizumab-awwb Compared With Bevacizumab in Patients With Cancer
Maher Alhaja, PharmD, BCOP; Candy Tsourounis, PharmD; Hansen Ho, PharmD, BCOP; Richard Fong, PharmD, BCOP
Read More
Case Reports, Lymphoma, Adverse Events, Methotrexate
Triamterene Cross-Reactivity With Methotrexate Immunoassay: Case Report of Falsely Delayed Methotrexate Clearance During Treatment of High-Grade B-Cell Lymphoma
Jameson B. Wood, PharmD, BCOP; Michael T. Brennan, PharmD; Lesley Wu, MD; Michelle A. Hankins, MD
Read More
Original Research, Leukemia, Adverse Events, Chemotherapy, Venetoclax
Safety of Venetoclax Without Dose Ramp-Up When Used in Combination With a Hypomethylating Agent for Acute Myeloid Leukemia
Brandon M. Gray, PharmD, BCPS; Sorana G. Ursu, PharmD, BCOP; Mohammad M. Alhousani, MD; Christina Caruso, MPAS, PA-C; Salman Fazal, MD
Read More
Original Research, Adverse Events, Immunotherapy, Infusion Issues
The Effect of Dosing Schedule on the Incidence of Immune-Related AEs and Infusion Reactions in Patients Receiving Immunotherapy
Solmaz Karimi, PharmD, MS; April K.S. Salama, MD; Brent A. Hanks, MD, PhD; Beiyu Liu, PhD; Alaattin Erkanli, PhD; Theresa Brown, PharmD, BCOP, CPP
Read More
Editorial
New Year, New HOP(A): Return of the Annual Conference Research Abstracts
Sara S. Kim, BS, PharmD, BCOP; Adam J. DiPippo, PharmD, BCOP
Read More
HOPA Abstracts
Assessing Student Pharmacists’ Knowledge and Perceptions of Financial Toxicity Concepts Introduced in an Oncology Pharmacotherapy Course
Abstract #CR01
Charles Wight, PharmD; Matthew DellaVecchia, PhD; Nicholas Chow, PharmD, BCOP; Monica Tadros, PharmD, BCPS, BCOP
Read More
HOPA Abstracts
Biodistribution and Shedding Analysis Following RP1 Oncolytic Immunotherapy Dosing in Patients From the IGNYTE Clinical Trial: Implications for Oncology Pharmacists
Abstract #CR02
Christina Davis, PharmD, BCOP; Praveen K. Bommareddy, PhD, BPharm, MS; Alina Monteagudo, PhD; Mohammed M. Milhem, MD; Joseph J. Sacco, MD; Tawnya Lynn Bowles, MD, et al.
Read More
HOPA Abstracts
Characterizing Second-Line and Beyond Treatments for Primary Central Nervous System Lymphomas
Abstract #CR03
Erin K. Yeung, PharmD, BCPS, BCOP; Brian Primeaux, PharmD, BCOP; Chelsea Luo, PharmD, BCOP; Caitlin Linger, PharmD, BCOP; Sheree Chen, PharmD, BCOP; Bryan Do, PharmD, BCOP
Read More
HOPA Abstracts
Coordinating Better Outcomes in Multiple Myeloma: An Educational Initiative to Elevate Pharmacist Leadership in Novel Antibodies and CAR-T Therapy
Abstract #CR04
Jeffrey Murray, PharmD, PVI; Carmine DeLuca; Michael Beyer, PVI; Zahra Mahmoudjafari, PharmD; R. Donald Harvey, PharmD
Read More
Page 19 of 196
Results 181 - 190 of 1953